In situ pharmacoproteomics for the prediction of efficacy and side effects
| Project/Area Number |
26640098
|
|---|
| Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor diagnostics
|
|---|
| Research Institution | National Institutes of Biomedical Innovation, Health and Nutrition |
|---|
Principal Investigator |
ADACHI JUN 国立研究開発法人医薬基盤・健康・栄養研究所, プロテオームリサーチプロジェクト, 研究員 (20437255)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2014: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
|
|---|
| Keywords | キナーゼ阻害剤 / プロテオミクス |
|---|
| Outline of Final Research Achievements |
We developed a 3D-Pharmacoproteomics (3D-PPx）method to identify targets of ATP-competitive kinase inhibitors at the various scale of concentrations and inhibition time points. We applied 3D-PPx to find targets of erlotinib, an EGFR inhibitor used as an anti-cancer drug. We confirmed that 3D-PPx can detect the effect of EGFR mutation using erlotinib-resistant NSCLC cells which express wild-type EGFR and erlotinib-sensitive NSCLC cells which express mutant EGFR. Furthermore, several target candidates of erlotinib were identified using 3D-PPx.
|
Report
(3 results)
Research Products
(3 results)
-
[Journal Article] Data for Proteomic Analysis of ATP-Binding Proteins and Kinase Inhibitor Target Proteins Using an ATP Probe.2015
Author(s)
Adachi, J., Kishida, M., Watanabe, S., Hashimoto, Y., Fukamizu, K., and Tomonaga, T.
-
Journal Title
Data in Brief
Volume: 5
Pages: 726-729
DOI
Related Report
Peer Reviewed / Open Access
-
-
